An Overview of Meningococcal Meningitis
What's the Treatment for Meningococcal Meningitis?
Meningococcal meningitis can cause death or serious complications, such as brain damage, paralysis, gangrene, or deafness. To prevent these problems, it's important to act quickly. Do not wait. Seek immediate medical attention. Go to an emergency room or call 911 if:
- You notice symptoms of meningococcal meningitis
- Symptoms do not improve with treatment
- You think you have been exposed to meningococcal meningitis
Tests can confirm a diagnosis of meningococcal meningitis. The doctor may start antibiotics, such as penicillin or ceftriaxone, by an IV, or intravenous line. You or your child may also need other medication to treat problems related to increased spinal fluid pressure. Doctors sometimes prescribe steroids.
If you or someone you love has come into close contact (via saliva or other oral secretions) with someone who has meningococcal meningitis -- such as at school, day care, work, or home -- it is very important to get antibiotics to prevent infection.
Are There Vaccines for Meningococcal Meningitis?
Meningococcal meningitis is a serious disease -- even with treatment. That's why prevention is a far better approach. The meningococcal vaccine can prevent meningitis infection. In the U.S., three types of meningococcal vaccines are used:
Meningococcal conjugate vaccine (MCV4) -- One of these vaccines, Menactra, is approved for people ages 9 months to 55. The other, Menveo, is used in those ages 2 through 55.
Meningococcal polysaccharide vaccine (MPSV4) -- This vaccine was approved in the 1970s and protects against most forms of meningococcal disease. This vaccine used is for people as young as 9 months and older than age 55.
Serogroup B Meningococcal B - There are two MenB vaccines. Trumenba (MenB-FHbp) and Bexsero (MenB-4C). Both are licensed for ages 10-24 but can be used in older patients.
Although they cannot prevent all types of meningococcal disease, both vaccines can prevent many types of the disease. Both are effective in nine out of 10 people. MCV4 tends to give longer protection and is better at preventing transmission of the disease.
Doctors recommend a dose of MCV4, which is given as a shot, for children at age 11, and then a booster shot at age 16. If the first dose is missed, the MCV4 can be administered between ages 13 and 15, followed by a booster dose between ages 16 and 18. Other people at risk should also consider getting a vaccine. That includes:
- People who think they've been exposed to meningococcal meningitis
- College freshmen living in dorms
- U.S. military recruits
- Travelers to areas of the world, such as Africa, where meningococcal disease is common
- People with a damaged spleen or with terminal complement component deficiency, which is an immune system disorder
- Lab personnel who are often exposed to the meningococcal bacteria